CJC-1295 & Ipamorelin Blend

• GH pulsatility enhancement (GHRH + GHS synergy)

• Lean‑mass support & body‑composition improvements

• Musculoskeletal recovery & connective‑tissue support

• Bone metabolism & osteoblastic activity

• Metabolic flexibility & lipid regulation

• Age‑related GH/IGF‑1 decline

• Sleep quality & circadian rhythm support

CJC‑1295 (without DAC)

• Stimulates GHRH receptors in the pituitary

• Enhances physiologic GH pulsatility

• Supports IGF‑1 elevation through natural GH signaling

• Avoids continuous GH elevation associated with exogenous GH therapy

Ipamorelin

• Selectively activates GHS‑R1a (ghrelin receptor)

• Triggers GH release with minimal cortisol, prolactin, or ACTH impact

• Supports recovery, lean‑mass development, and neuroendocrine balance

Combined Effect

• Dual stimulation of GH axis (GHRH + GHS synergy)

• Amplified physiologic GH pulses

• More natural IGF‑1 elevation

• Reduced endocrine spillover compared to older secretagogues

This blend is composed of research‑grade peptides and is not FDA‑approved for therapeutic, anti‑aging, or performance use. Most available data come from preclinical studies and early‑stage research. Even so, the combination has gained significant interest in wellness, performance, and endocrine‑focused research communities, supported by substantial anecdotal reporting. While more large‑scale studies are needed, the blend’s dual‑pathway selectivity and promising early findings continue to drive scientific and community interest in GH‑modulating peptide research.

1. Teichman, S. L., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J. P., & Frohman, L. A. (2006). Prolonged stimulation of growth hormone (GH) and insulin‑like growth factor‑I (IGF‑I) secretion by CJC‑1295, a long‑acting GH‑releasing hormone analog. Journal of Clinical Endocrinology & Metabolism, 91(3), 799–805.

2. Castaigne, J. P., et al. (2004). Pharmacodynamic effects of CJC‑1295, a long‑acting GHRH analog, in healthy adults. Clinical Pharmacology & Therapeutics, 76(3), 217–227.

3. Raun, K., Hansen, B. S., Johansen, N. L., Thøgersen, H., Madsen, K., & Thim, L. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 139(5), 552–561.

4. Raun, K., et al. (1999). Pharmacological profile of Ipamorelin: selective GH release without effects on prolactin or cortisol. Journal of Endocrinology, 161(3), 481–489.

5. Johansen, N. L., et al. (1997). Design and development of selective GH secretagogues: the Ipamorelin model. Peptides, 18(9), 1265–1271.

CURRENT BATCH LOT NUMBER: CP102026-04-07

CERTIFICATE OF ANALYSIS – TGMPURE CJC-1295 IPAMORELIN BLEND 10 MG (CP102026-04-07)